These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19761738)

  • 1. Economic consequences to society of pandemic H1N1 influenza 2009 - preliminary results for Sweden.
    Brouwers L; Cakici B; Camitz M; Tegnell A; Boman M
    Euro Surveill; 2009 Sep; 14(37):. PubMed ID: 19761738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.
    Khazeni N; Hutton DW; Garber AM; Hupert N; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):829-39. PubMed ID: 20008759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries for patients. Assessing the best way to prevent spread of influenza.
    Ann Intern Med; 2009 Dec; 151(12):I31. PubMed ID: 20008744
    [No Abstract]   [Full Text] [Related]  

  • 4. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.
    Sander B; Bauch CT; Fisman D; Fowler RA; Kwong JC; Maetzel A; McGeer A; Raboud J; Scales DC; Gojovic MZ; Krahn M
    Vaccine; 2010 Aug; 28(38):6210-20. PubMed ID: 20643091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tool for the economic analysis of mass prophylaxis operations with an application to H1N1 influenza vaccination clinics.
    Cho BH; Hicks KA; Honeycutt AA; Hupert N; Khavjou O; Messonnier M; Washington ML
    J Public Health Manag Pract; 2011; 17(1):E22-8. PubMed ID: 21135651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public Health Measures in an Influenza Pandemic - the importance of surveillance.
    Nicoll A; ; Ciancio B; de la Hoz KF; Kreidl P; Needham H; Varela C; Vasconcelos P; Webber JT; Wurz A
    Euro Surveill; 2007 Nov; 12(11):E071101.4. PubMed ID: 17997909
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost analysis of influenza vaccine administration in Fayette County, Kentucky, 2005-2007.
    Kryscio KE
    Public Health Rep; 2010; 125(2):358-63. PubMed ID: 20297765
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantifying the economic value and quality of life impact of earlier influenza vaccination.
    Lee BY; Bartsch SM; Brown ST; Cooley P; Wheaton WD; Zimmerman RK
    Med Care; 2015 Mar; 53(3):218-29. PubMed ID: 25590676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Economic Consequences of an Influenza Outbreak in the United States.
    Prager F; Wei D; Rose A
    Risk Anal; 2017 Jan; 37(1):4-19. PubMed ID: 27214756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.
    Newall AT; Wood JG; Oudin N; MacIntyre CR
    Emerg Infect Dis; 2010 Feb; 16(2):224-30. PubMed ID: 20113551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stagnating influenza vaccine coverage rates among high-risk groups in Poland and Sweden in 2003/4 and 2004/5.
    Kroneman MW; van Essen GA
    Euro Surveill; 2007 Apr; 12(4):E1-2. PubMed ID: 17991383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness study on influenza prevention in Hong Kong.
    Fitzner KA; Shortridge KF; McGhee SM; Hedley AJ
    Health Policy; 2001 Jun; 56(3):215-34. PubMed ID: 11399347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitigation of pandemic influenza: review of cost-effectiveness studies.
    Lugnér AK; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):547-58. PubMed ID: 19941432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost comparison of 2 mass vaccination campaigns against influenza A H1N1 in New York City.
    Kansagra SM; McGinty MD; Morgenthau BM; Marquez ML; Rosselli-Fraschilla A; Zucker JR; Farley TA
    Am J Public Health; 2012 Jul; 102(7):1378-83. PubMed ID: 22676501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influenza--old medical problem].
    Brydak LB
    Przegl Epidemiol; 2006; 60 Suppl 1():23-7. PubMed ID: 16909771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk groups and other target groups - preliminary ECDC guidance for developing influenza vaccination recommendations for the season 2010-11.
    Nokleby H; Nicoll A
    Euro Surveill; 2010 Mar; 15(12):. PubMed ID: 20350496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Well-functioning strategy for the A/H1N1 pandemic in Varmland. A preliminary summary].
    Wik O
    Lakartidningen; 2010 Jun 16-29; 107(24-25):1630-3. PubMed ID: 20687426
    [No Abstract]   [Full Text] [Related]  

  • 20. From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination.
    Lee BY; Bacon KM; Donohue JM; Wiringa AE; Bailey RR; Zimmerman RK
    Vaccine; 2011 Mar; 29(11):2149-58. PubMed ID: 21215340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.